Esperion Therapeutics, Inc.

NASDAQ:ESPR

Biotechnology

Healthcare
$3.18 -0.32%

+$0.00 today

Market cap
$661.15M
Beta
1.07
P/E (TTM)
-107.3
EPS (TTM)
-$0.03
52W Low $0.95High $4.18

Volume 0.00M

Average 12.29M

ESPR Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

Esperion Therapeutics, Inc.NASDAQ: ESPR

Weighted Avg Shares (Diluted) · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares (diluted) growth accelerates

Q1 FY2026 weighted avg shares (diluted) of 251.35M shares rose 28.2% year over year, ahead of the +20.1% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it fell 11.7% from the prior quarter. Over 3 fiscal years it compounded at +46.3% a year.

Context

  • Weighted avg shares (diluted) increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +28.2% holds above the trailing-twelve-month pace of +20.1%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
251.35M-11.7% QoQ
Last fiscal yearDec 2025
207.87M+11.0% YoY
LTMMar 2026
232.73M+20.1% YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+28.2%——
1 year+11.0%——
3-year CAGR+46.3%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
207.87M USD
Year-over-year change
+11.0%
4-year CAGR
+63.8%

Weighted Avg Shares (Diluted) vs competitors

How ESPR compares with its peers on the latest reported figures

  • ESPR's LTM Mar 2026 weighted avg shares (diluted) of 232.73M shares is the 2nd highest of the 10 companies compared; the peer median is 82.59M shares.
  • Its year-over-year change of +20.1% is the 5th highest of 10, against a peer median of +3.4%.
  • Over three fiscal years its annual growth of +46.3% compares with a peer median of +14.6%.
ESPR Competitors Peer median
Weighted Avg Shares (Diluted) for ESPR and competitors
Company Period LTM YoY 3-year CAGR
SNDLSNDL Inc.LTM Mar 2026261.05M -0.7%+3.9%
ESPREsperion Therapeutics, Inc.LTM Mar 2026232.73M +20.1%+46.3%
ABSIAbsci CorporationLTM Mar 2026143.73M +23.4%+14.6%
AQSTAquestive Therapeutics, Inc.LTM Mar 2026113.62M +23.3%+35.8%
OLMAOlema Pharmaceuticals, Inc.LTM Mar 202691.34M +41.8%+29.6%
CRVSCorvus Pharmaceuticals, Inc.LTM Mar 202682.59M +22.4%+19.7%
SIGASIGA Technologies, Inc.LTM Mar 202671.65M -0.0%-0.9%
EBSEmergent BioSolutions Inc.LTM Mar 202654.9M -0.0%+4.2%
RGNXREGENXBIO Inc.LTM Mar 202651.84M +1.8%+6.1%
OFIXOrthofix Medical Inc.LTM Mar 202639.93M +3.4%+25.7%
Peer median (excluding ESPR) 82.59M+3.4%+14.6%

Competitors are the stored peer set for ESPR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue78.45M75.48M116.33M332.31M403.14M
Cost of Revenue14.22M26.97M43.27M68.6M129.22M
Gross Profit64.23M48.51M73.07M263.71M273.91M
Gross Margin81.9%64.3%62.8%79.4%67.9%
Research & Development105.98M118.93M86.11M46.24M47.85M
Selling, General & Admin184.99M109.08M142.52M163.07M165.79M
Operating Expenses290.96M228.01M228.63M209.31M213.64M
Depreciation & Amortization612K500K164K63K105K
EBITDA(222.14M)(176.35M)(150.11M)7.57M63.87M
EBITDA Margin-283.2%-233.7%-129.0%2.3%15.8%
Operating Income(226.73M)(179.5M)(155.56M)54.4M60.27M
Operating Margin-289.0%-237.8%-133.7%16.4%15.0%
Interest Income00003.5M
Interest Expense46.35M56.81M58.98M59.25M84.6M
Other Income / Expenses(42.38M)(54.16M)(53.69M)(106.15M)(81.11M)
Income Before Tax(269.11M)(233.66M)(209.25M)(51.75M)(20.84M)
Pre-Tax Margin-343.0%-309.6%-179.9%-15.6%-5.2%
Income Tax Expense00001.84M
Net Income(269.11M)(233.66M)(209.25M)(51.75M)(22.68M)
Net Margin-343.0%-309.6%-179.9%-15.6%-5.6%
EPS (Basic)(11.03)(4.33)(2.03)(0.28)(0.11)
EPS (Diluted)(11.03)(4.33)(2.03)(0.28)(0.11)
Weighted Avg Shares28.9M66.41M103.11M187.18M207.87M
Weighted Avg Shares (Diluted)28.9M66.41M103.11M187.18M207.87M

Esperion Therapeutics, Inc.

NASDAQ:ESPR

Intrinsic Alpha fair value

Locked

Current Price

$3.18

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.